We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The change in monthly employee pay and employee status attributable to having had bariatric surgery, in different time periods after surgery, compared to six-months before surgery.
How to use a case-control study to evaluate your digital health product.
Local authorities and businesses are working with families and schools to reduce childhood obesity.
Statistics from a variety of sources on obesity, physical activity and diet.
Foresight project looking at how we can respond to rising levels of obesity in the UK.
As with any medicine, the MHRA will keep the safety and effectiveness of Wegovy under close review.
The Medicines and Healthcare products Regulatory Agency (MHRA) approved a maximum dose of up to 7.2mg per week of semaglutide (Wegovy) on 6 January 2026.
A guide and set of resources to support local authorities with implementing a whole systems approach to address obesity and promote a healthy weight.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).